A randomized controlled trial is conducted investigating the effects of different diagnostic imaging modalities on breast cancer mortality. 8,000 women are randomized to receive either conventional mammography or conventional mammography with breast MRI. The primary outcome is survival from the time of breast cancer diagnosis. The conventional mammography group has a median survival after diagnosis of 17.0 years. The MRI plus conventional mammography group has a median survival of 19.5 years. If this difference is statistically significant, which form of bias may be affecting the results?

Because this study is a randomized controlled trial, it is free of bias

A 55-year-old man presents for physical and preventive health screening, specifically for prostate cancer. He has not been to the doctor in a long time. Past medical history is significant for hypertension that is well-managed. Current medication is hydrochlorothiazide. He has one uncle who died of prostate cancer. He drinks one or two alcoholic drinks on the weekends and does not smoke. Today his temperature is 37.0°C (98.6°F), blood pressure is 125/75 mm Hg, pulse is 82/min, respiratory rate is 15/min, and oxygen saturation is 99% on room air. There are no significant findings on physical examination. Which of the following would be the most appropriate recommendation for prostate cancer screening in this patient?

Contrast CT of the abdomen and pelvis

No screening indicated at this time

Study X examined the relationship between coffee consumption and lung cancer. The authors of Study X retrospectively reviewed patients' reported coffee consumption and found that drinking greater than 6 cups of coffee per day was associated with an increased risk of developing lung cancer. However, Study X was criticized by the authors of Study Y. Study Y showed that increased coffee consumption was associated with smoking. What type of bias affected Study X, and what study design is geared to reduce the chance of that bias?

Observer bias; double blind analysis

A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?

Cancer screening does not fit into these categories

A 46-year-old woman presents to her primary care physician for her annual examination. At her prior exam one year earlier, she had a Pap smear which was within normal limits. Which of the following health screenings is recommended for this patient?

Blood glucose and/or HbA1c screening

Blood pressure at least once every 3 years

A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?

Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes

Perform 3-hour oral glucose tolerance test at 16 weeks

Diagnose gestational diabetes based on random glucose and begin treatment

Perform 1-hour glucose challenge test now

Defer screening until 24-28 weeks gestation per routine protocol

A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?

Repeat colonoscopy in 5-10 years

Annual fecal immunochemical testing

A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?

Refer for genetic counseling and consider expanded testing with breast MRI screening

Begin mammography at age 35 and annually thereafter

Recommend clinical breast exam every 6 months only

Reassure that negative BRCA testing indicates average risk

Limitations and controversies in screening | Screening guidelines

Limitations and controversies in screening - Screening's Gray Areas

Screening tests are not perfect and can introduce several biases and challenges that complicate their interpretation and utility.

Bias Type	Description	Classic Example
Lead-Time Bias	Screening detects a disease earlier, but the time of death remains the same. It creates an artificial inflation of survival time.	A slow-growing tumor is found 3 years earlier via screening, but the patient's date of death is unchanged. The survival from diagnosis appears longer.
Length-Time Bias	Screening is more likely to detect slow-growing, indolent diseases with a long preclinical phase, while missing aggressive, rapidly fatal diseases.	Screening mammography is more apt to find a slow-growing ductal carcinoma than a rapidly progressive inflammatory breast cancer.

-   Detecting diseases that would never have become clinically apparent or caused harm in a patient's lifetime.
-   Leads to overtreatment, exposing patients to the risks of therapy without any benefit.

False Positives & Negatives:
- False Positives: A positive result when no disease is present. Causes significant patient anxiety, leads to unnecessary, often invasive, follow-up tests, and ↑ healthcare costs.
- False Negatives: A negative result when disease is present. Provides false reassurance and can delay diagnosis and treatment.
Additional Burdens:
- Patient Anxiety: The stress of the screening process, waiting for results, and dealing with ambiguous findings.
- Costs: Direct costs of the tests and the significant downstream costs of working up false-positive results.

⭐ The controversy surrounding PSA screening for prostate cancer is a classic example, as it detects many indolent tumors, leading to overdiagnosis and overtreatment.

High‑Yield Points - ⚡ Biggest Takeaways

Lead-time bias gives the illusion of increased survival by simply advancing the diagnosis time without extending life.

Length-time bias means screening is more likely to find slow-growing, less aggressive cancers, which inherently have a better prognosis.

Overdiagnosis is a critical harm, resulting in the treatment of indolent conditions that would never have caused symptoms.

False positives trigger patient anxiety and unnecessary invasive procedures, while false negatives offer dangerous false reassurance.

Screening harms include radiation exposure, procedural complications, and the psychological stress of a potential diagnosis.

Limitations and controversies in screening

Limitations and controversies in screening

On this page

Limitations and controversies in screening - Screening's Gray Areas

High‑Yield Points - ⚡ Biggest Takeaways

Practice Questions: Limitations and controversies in screening

Flashcards: Limitations and controversies in screening

Enjoying this lesson?